Glucagon is released from ␣-cells present in intact pancreatic islets at glucose concentrations below 4 mM, whereas higher glucose levels inhibit its secretion. The mechanisms underlying the suppression of ␣-cell secretory activity are poorly understood, but two general types of models have been proposed as follows: direct inhibition by glucose or paracrine inhibition from non-␣-cells within the islet of Langerhans. To identify ␣-cells for analysis, we utilized transgenic mice expressing fluorescent proteins targeted specifically to these cells. Measurements of glucagon secretion from pure populations of flow-sorted ␣-cells show that contrary to its effect on intact islets, glucose does stimulate glucagon secretion from isolated ␣-cells. This observation argues against a direct inhibition of glucagon secretion by glucose and supports the paracrine inhibition model. Imaging of cellular metabolism by two-photon excitation of NAD(P)H autofluorescence indicates that glucose is metabolized in ␣-cells and that glucokinase is the likely rate-limiting step in this process. Imaging calcium dynamics of ␣-cells in intact islets reveals that inhibiting concentrations of glucose increase the intracellular calcium concentration and the frequency of ␣-cell calcium oscillations. Application of candidate paracrine inhibitors leads to reduced glucagon secretion but did not decrease the ␣-cell calcium activity. Taken together, the data suggest that suppression occurs downstream from ␣-cell calcium signaling, presumably at the level of vesicle trafficking or exocytotic machinery.Endocrine function of the islet of Langerhans is critical for the regulation of blood glucose homeostasis. Mouse islets are "micro-organs" composed of insulin-secreting -cells (70 -85% of the cells), glucagon-secreting ␣-cells (10 -15%), along with other cell types (1, 2). Insulin and glucagon constitute a bi-hormonal system integral for maintaining normal blood glucose levels. Insulin lowers blood glucose by allowing tissues to absorb, metabolize, and store glucose. Glucagon, on the other hand, plays a protective role when blood glucose levels fall by stimulating hepatic glucose output via glycogenolysis and gluconeogenesis (3). Type 1 and late type 2 diabetes have been associated with elevated levels of glucagon that exacerbate the chronic hyperglycemia caused by insulin deficiency (4). Also, patients under treatment with insulin or insulin secretagogues often fail to secrete a sufficient amount of glucagon during hypoglycemic episodes (5). This reduced glucagon response increases the risk of severe iatrogenic hypoglycemia.In normal physiology, glucagon secretion is maximal at low blood glucose levels (Ͻ4 mM), whereas higher glucose concentrations stimulate insulin release and reduce glucagon secretion. The cellular mechanisms leading to insulin secretion are fairly well understood. -Cell glucose transporter (i.e. GLUT-2) and glucokinase ensure that glucose enters the glycolytic pathway (6 -8). Glucose metabolism leads to an increase in ATP to ADP ratio...